Methods for increasing efficiency of gene editing in cells

US12325865B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12325865-B2
Application numberUS-201816482294-A
CountryUS
Kind codeB2
Filing dateJan 31, 2018
Priority dateFeb 1, 2017
Publication dateJun 10, 2025
Grant dateJun 10, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure provides methods of improving nuclease-mediated gene targeting frequencies in cells using PFTα or bFGF.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of making a population of PERV-free porcine cells, the method comprising: (a) genetically modifying a primary porcine cell which comprises porcine endogenous retrovirus (PERV) genes by providing a vector comprising a nucleic acid sequence which encodes a nuclease and three sgRNAs to the primary porcine cell, wherein the nuclease is expressed and cuts the PERV genes, thereby producing a genetically modified, PERV-free, primary porcine cell, (b) providing an exogenous pifithrin α (PFTα) and a basic fibroblast growth factor (bFGF) to the primary porcine cell concomitant with step (a), (c) contacting the primary porcine cell with a large SV40 T antigen to increase targeting efficiency, (d) isolating the genetically modified, PERV-free primary porcine cell, and expanding the genetically modified, PERV-free porcine cell to a population of PERV-free porcine cells, wherein the population of PERV-free porcine cells exhibits a lack of PERV transmission as evidenced by co-culturing a cell with the population of PERV-free porcine cells. 2. The method of claim 1 , wherein the nuclease is a Cas nuclease, a Cas nickase, or a nuclease null Cas bound to a nuclease. 3. The method of claim 2 , wherein the nuclease is the Cas nuclease. 4. The method of claim 3 , wherein the Cas nuclease is Cas9. 5. The method of claim 1 , wherein the PERV genes comprise PERV pol genes. 6. The method of claim 1 , wherein of the PFTα and the bFGF inhibit apoptosis in the primary porcine cell. 7. The method of claim 1 , wherein the PFTα and the bFGF increase gene editing rates in the primary porcine cell. 8. The method of claim 1 , wherein the PFTα and the bFGF increase a cell survival rate in the primary porcine cell.

Assignees

Inventors

Classifications

  • Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites · CPC title

  • Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

  • involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

  • basic FGF [bFGF] · CPC title

  • General methods applicable to biologically active non-coding nucleic acids · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12325865B2 cover?
The present disclosure provides methods of improving nuclease-mediated gene targeting frequencies in cells using PFTα or bFGF.
Who is the assignee on this patent?
Harvard College
What technology area does this patent fall under?
Primary CPC classification C12N15/907. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 10 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).